BW-24

BW-24 is an investigational small interfering RNA (siRNA) therapeutic being developed by Shanghai Argo Biopharmaceutical for the treatment of cardiovascular diseases. As part of Argo's proprietary RNAi platform, BW-24 is designed to silence the expression of a specific, though currently undisclosed, disease-relevant gene to provide long-lasting therapeutic effects. The drug likely utilizes a liver-targeted delivery system to achieve potent and durable knockdown of its target protein, which is involved in the pathogenesis of cardiovascular conditions. It is currently in the early stages of development within the company's extensive pipeline of RNA-based therapies.